Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections
- Sponsor
- David Moss
- Study ID
- NCT07610967
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- COVID-19 Respiratory Infection
- Influenza
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- RD-X19 — DEVICE* Subject will be given the RD-X19 device and shown how to use the device * Subjects will be instructed to use the device for 5 minutes every other day * Subject will be given "Instructions for Treatment" handout
- RD-X19 Sham — DEVICE* Subject will be given the sham RD-X19 device and shown how to use the device * Subjects will be instructed to use the sham device for 5 minutes every other day * Subject will be given "Instructions for Treatment" handout
Study Details
The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld, can be self-administered, and has been shown to be safe in invivo studies.
Key Dates
- First listed
- May 28, 2026
- Start date
- Jun 30, 2026
- Status verified
- May 2026
- Primary completion
- Jun 30, 2028
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 130 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 1: Active RD-X19 every other day for 3 months
- Sham Comparator: Group 2: Sham RD-X19 every other day for 3 months
Primary Outcome Measure
difference in PCR confirmed URI (any virus) [ Time Frame: visit 2 (week 2), visit 3 (week 4), visit 4 (week 6), visit 5 (week 8), visit 6 (week 10), visit 7 (week 12) ]
Central Contacts
- Sandra Huffman7026533583
Related Studies
- Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Influenza Immunization in Adults Over Age 75Recruiting · Johns Hopkins University · Baltimore, Maryland
- Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised PatientsPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Observational Digital Biomarker Discovery in Respiratory Virus Challenge StudiesRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland